-
Media Release
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
-
Media Release
Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media Release
FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-
Media Release
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media Release
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia